Articles written by: Davis Scott

Reviewing Altimmune Inc. (ALT)’s and Axsome Therapeutics Inc. (NASDAQ:AXSM)’s results

As Biotechnology companies, Altimmune Inc. (NASDAQ:ALT) and Axsome Therapeutics Inc. (NASDAQ:AXSM) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune Inc. 3 3.18 N/A -15.41 […]

Reviewing New Mountain Finance Corporation (NMFC)’s and Royce Global Value Trust Inc. (NYSE:RGT)’s results

New Mountain Finance Corporation (NYSE:NMFC) and Royce Global Value Trust Inc. (NYSE:RGT) are two firms in the Asset Management that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings […]

Reviewing Gridsum Holding Inc. (GSUM)’s and Verb Technology Company Inc. (NASDAQ:VERB)’s results

Gridsum Holding Inc. (NASDAQ:GSUM) and Verb Technology Company Inc. (NASDAQ:VERB) have been rivals in the Application Software for quite some time. Below is a review of each business including various aspects such as dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio […]

Comparison of NovaBay Pharmaceuticals Inc. (NBY) and Emergent BioSolutions Inc. (NYSE:EBS)

NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY) and Emergent BioSolutions Inc. (NYSE:EBS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio […]

Urovant Sciences Ltd. (UROV) and Edge Therapeutics Inc. (:) Contrasting side by side

As Biotechnology companies, Urovant Sciences Ltd. (NASDAQ:UROV) and Edge Therapeutics Inc. (:) are our subject to compare. And more specifically their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urovant Sciences Ltd. 9 0.00 […]

Evelo Biosciences Inc. (EVLO) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Contrasting side by side

We are contrasting Evelo Biosciences Inc. (NASDAQ:EVLO) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evelo Biosciences Inc. 8 […]

The Carlyle Group L.P. (TCGP)’s Financial Results Comparing With Principal Real Estate Income Fund (NYSE:PGZ)

Since The Carlyle Group L.P. (NASDAQ:TCGP) and Principal Real Estate Income Fund (NYSE:PGZ) are part of the Asset Management industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies. Valuation and Earnings Gross Revenue Price/Sales Ratio […]

Comparing of Esperion Therapeutics Inc. (ESPR) and AzurRx BioPharma Inc. (NASDAQ:AZRX)

Esperion Therapeutics Inc. (NASDAQ:ESPR) and AzurRx BioPharma Inc. (NASDAQ:AZRX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio […]